One study showed small cell lung cancer (SCLC) tumors with higher DNA damage response (DDR) activity were initially more sensitive to chemotherapy but had worse overall survival.
Researchers identified 3 distinct DNA damage response (DDR) phenotypes in small cell lung cancer (SCLC) that may offer some insight into why some tumors respond well to frontline chemotherapy while others rapidly develop resistance.1
These findings, published in Molecular Cancer, suggest that DDR status at diagnosis could shape tumor evolution and influence treatment outcomes.
SCLC is one of the most aggressive and hardest-to-treat lung cancers.2 While most patients initially respond to chemotherapy, resistance emerges quickly, leading to disease progression. In the new study, researchers found that tumors with higher DDR activity were initially more sensitive to chemotherapy but had worse overall survival, suggesting a paradox where DNA repair mechanisms may contribute to resistance over time.1
DNA damage response status may affect how small cell lung cancer tumors evolve after chemotherapy. | Image credit: Nattakorn – stock.adobe.com
“Together, our results suggest a model where high levels of replication stress and cell-intrinsic DNA damage drive compensatory upregulation of the DDR machinery in treatment naïve tumors, potentially priming SCLCs for resistance to DNA damaging therapies and ultimately leading to poor patient outcomes,” the authors wrote.
They analyzed tumor samples from clinical trials and model systems, categorizing them into 3 DDR clusters:
Although DDR High tumors shrank more in response to platinum-based chemotherapy, they also developed resistance quickly, suggesting DNA repair mechanisms may help tumors evade long-term treatment effects.
“Our finding that DDR High and Intermediate patients have numerically shortened overall survival following frontline chemotherapy, compared to DDR Low, may be explained by the fact that many additional lines of therapy in SCLC are also DNA-damage based.” the researchers wrote. “It is possible that as these tumors quickly develop resistance to frontline DNA-damaging therapies, they may be primed for cross-resistance to additional lines of therapy with similar mechanisms of action, a phenomena recently confirmed in SCLC.”
The study also demonstrated a possible influence of DDR status on how tumors evolve after chemotherapy. Higher DDR activity was linked to immune evasion, meaning these tumors had lower levels of immune cell infiltration and fewer inflammatory markers, potentially making them less responsive to immunotherapy.
Some DDR Intermediate and High tumors also switched subtypes after treatment, acquiring features that should theoretically, according to the researchers, make them more vulnerable to immunotherapy. However, patients with these “inflamed” subtype switching tumors had worse overall and progression-free survival outcomes following chemoimmunotherapy compared with those with de novo SCLC-I tumors.
“When analyzing these samples further, we found these plastic tumors had some of the lowest initial immune infiltrates before treatment across a third independent cohort of treatment naïve SCLC tumors,” the researchers added. “These data suggests that DDR-specific immune cell poor microenvironments may be linked to the ability of SCLC cells to progress to an ‘inflamed’ state but not receive durable benefit from frontline chemoimmunotherapy.”
Despite these findings, the researchers acknowledged the need for larger clinical trials to validate their findings, as the current study was limited by sample size, retrospective design, lack of matched genomic profiles, and other factors.
“Our work demonstrates that initial DDR status plays a key role in shaping SCLC phenotypes and may be associated with chemotherapy response and patterns of tumor evolution following frontline therapy,” the researchers wrote. “Future work targeting DDR cluster specific phenotypes will be instrumental for ultimately improving SCLC patient outcomes.”
References
FDA Approves Cabozantinib for Advanced Pancreatic Neuroendocrine Tumors
March 26th 2025With strong progression-free survival benefits demonstrated in the CABINET trial and updates to National Comprehensive Cancer Network guidelines, this approval reinforces cabozantinib’s role in improving outcomes for patients facing these challenging cancers.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Texas Oncology to Roll Out Canopy for ePROs After Head-to-Head Pilot
March 18th 2025Debra Patt, MD, PhD, MBA, executive vice president of Public Policy and Strategy for Texas Oncology, said the practice received positive feedback from nurses and patients during a pilot that concluded in February.
Read More
Cancer Labels on Alcohol? Ireland, Where Pubs Still Rule, Will Have Them by Next Year
March 17th 2025As St. Patrick's Day brings global celebrations involving alcohol, Ireland looks forward to rethinking excess consumption with a new tool set to arrive next year: the world's most comprehensive alcohol warning label.
Read More